ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.

Lung Cancer

Palliative Care

Symptom Management

Charles F. von Gunten, MD, PhD

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Prostate Cancer

Christian Carrie, MD and Celestia S. Higano, MD

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).

Breast Cancer

Nicholas C. Turner, MD, PhD

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Jul

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies

FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer

MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era

Global Breast Cancer Survival Estimates: WHO Analysis

Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer